Don’t miss the full story, whose reporting from Tom Murphy at The Associated Press is the basis of this AI-assisted article.
Pfizer’s fall COVID-19 vaccine sales have dropped 25% following the CDC’s decision to stop universally recommending the shots, creating confusion among consumers and health care providers.
Some key facts:
• Pfizer’s U.S. Comirnaty COVID-19 vaccine sales fell 25% in the third quarter to $870 million from $1.16 billion the previous year.
• The CDC stopped recommending COVID-19 vaccines for everyone and instead left the decision to individual patients and their doctors.
• Updated vaccine approval came several weeks later than usual this year, contributing to reduced sales.
• Health Secretary Robert F. Kennedy Jr.’s advisers influenced the CDC’s new recommendations, departing from previous guidance.
• Before this year, U.S. health officials recommended annual COVID-19 boosters for all Americans ages 6 months and older.
• The policy shift created confusion at drugstores, with some locations initially requiring prescriptions or asking about underlying health conditions.
• Moderna’s Spikevax vaccine sales are expected to drop approximately 50% in the third quarter, according to Wall Street analysts.
• CVS Health announced it will not require prescriptions for COVID-19 vaccines at its stores and clinics following the confusion.
READ MORE: Pfizer COVID-19 vaccine sales tumble after government guidance on the shots narrows
This article is written with the assistance of generative artificial intelligence based solely on Washington Times original reporting and wire services. For more information, please read our AI policy or contact Ann Wog, Managing Editor for Digital, at awog@washingtontimes.com
The Washington Times AI Ethics Newsroom Committee can be reached at aispotlight@washingtontimes.com.
